RT Journal Article
SR Electronic
T1 Unravelling the Cost of Biological Strategies in Rheumatoid Arthritis: A Kaleidoscope of Methodologies, Interpretations, and Interests
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.201510
DO 10.3899/jrheum.201510
A1 Johannes W.G.  Jacobs
A1 Maxime M.A.  Verhoeven
A1 Paco M.J.  Welsing
YR 2021
UL http://www.jrheum.org/content/early/2021/05/11/jrheum.201510.abstract
AB In this issue of The Journal of Rheumatology, Müskens, et al describe the effect of the introduction of an etanercept (ETN) biosimilar on antirheumatic medication cost1. After a Dutch rheumatology department launched this biosimilar as a substitute for the more expensive biologic ETN, the accumulated 3-monthly antirheumatic medication cost in that hospital pertaining to in- and outpatients with rheumatoid arthritis (RA), mainly consisting of cost of biologic disease-modifying antirheumatic drugs (bDMARD), decreased, as expected.